Aegis Sciences Corporation, a health care testing lab based in Nashville, TN, is pleased to announce this year’s first bi-annual update to its novel psychoactive substance (NPS) testing menu.
Aegis regularly updates its testing menu based on recommendations established collaboratively by the Center for Forensic Science Research and Education (CFSRE) and the Society of Forensic Toxicologist (SOFT) NPS Committee. Updates to the testing menu include CFSRE’s tier one and tier two scope recommendations for Quarter 4 of 2024.
“Aegis remains focused on tracking the evolving landscape of novel psychoactive substances,” said Dr. Rebecca Heltsley, Senior Vice President, Research and Development at Aegis Sciences Corporation. “Our R&D team optimizes detection of these compounds in urine and oral fluid in order to provide the most complete, accurate results.”
Aegis’s NPS testing menu is reviewed regularly to update the offering in a manner that allows it to maintain clinical relevance. Updates will include etomidate, a sedative hypnotic drug identified in the illicit drug supply, 4Cl-MDMB-BUTINACA, a new synthetic cannabinoid and multiple synthetic stimulants and designer opioids (including newly observed nitazene analogs such as fluetonitazene and n-pyrrolidino fluetonitazene which have been demonstrated to be significantly more potent than fentanyl). “These updates provide clinicians with critical information to help inform appropriate treatment decisions based on what novel substances are in the current drug supply,” said Dr. Josh Schrecker, Sr. Dir. of Clinical Affairs at Aegis Sciences Corporation.
With the launch of Aegis’s NPS data visualization dashboard in February 2025, clinicians, public health officials, and policymakers will be able to see the prevalence and distribution of these newly added substances in real-time once they are added to our menu and are detected in definitive testing results analyzed by Aegis.
Health care practitioners can learn more about the expanded testing menu here.
About Aegis Sciences Corporation
Founded in 1990, Aegis Sciences Corporation is a laboratory sciences company based in Nashville, Tenn., that provides science-driven testing and consulting services for clients such as health care providers, pharmaceutical companies, professional and amateur sports organizations, leading college and university athletic programs, Fortune 500 corporations, and government agencies throughout the United States. For more information, please visit http://www.aegislabs.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250603553521/en/
“These updates provide clinicians with critical information to help inform appropriate treatment decisions based on what novel substances are in the current drug supply,” said Dr. Josh Schrecker, Sr. Dir. of Clinical Affairs at Aegis Sciences Corporation.
Contacts
Stephanie Protz
Sr. Manager, Marketing Communications
stephanie.protz@aegislabs.com
